US board-certified medical oncologist with extensive global clinical and regulatory experience advancing oncology medicines from early development stages through to approval –
– Quanta is developing next-generation small-molecule cancer medicines by selectively targeting protein interactions that are key to oncogenic RAS activity –
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, today announced the appointment of Dr. Leonardo Faoro as Chief Medical Officer. Dr. Faoro brings more than 13 years of global clinical and regulatory experience advancing oncology medicines from early development stages through to approval, most recently serving as Senior Vice President and Early Clinical Development Lead at Exelixis, where he provided strategic leadership to expand the company's early clinical oncology pipeline and advance development candidates into the clinic.
First-generation KRAS inhibitors have provided clinical benefit in certain